Abstract
A total of 44 patients with previously untreated, non-resectable non-small-cell lung cancer (NSCLC) were treated with 4′-iodo-4′-deoxydoxorubicin (IDX), which is an analogue of doxorubicin with less cardiotoxicity. Patients received 80 mg/m2 i. v. every 3 weeks. Dose reductions were carried out for haematological toxicity. Response was assessed prior to each treatment according to WHO criteria. Among the 43 evaluable patients, 1 (2%; 95% confidence limits, 0–8%) achieved a partial response. Leucocytopenia of WHO grade 3 or 4 occurred in 64% of patients and corresponding thrombocytopenia grade 3 or 4 occurred in 30%. Of the 26 patients who were evaluated by measurements of the left ventricular ejection fraction (LVEF), 4 had a decline in LVEF of more than 15%, and 2 patients developed congestive heart failure. Myocardial biopsies were not done. In conclusion, IDX is not active in NSCLC at the applied dose and on the schedule used. Moreover, it does not seem possible to increase the dose intensity further due to the observed toxicity.
This is a preview of subscription content, log in via an institution to check access.
References
Alakl M, Orlandi F, Robert J, Fragu P, Munck JN, Carde P, Hurteloup P, Armand JP (1990) Phase I trial and pharmacokinetic (PK) study of 4′-iodo-4′-deoxydoxorubicin (IDOX) in i. v. bolus every 3 weeks (abstract). Ann Oncol 1 [Suppl]: 38
Barbieri B, Giuliani FC, Bordoni T, Casazza AM, Geroni C, Bellini O, Suarato A, Gioia B, Penco S, Arcamone F (1987) Chemical and biological characterization of 4′-iodo-4′-deoxydoxorubicin. Cancer Res 47: 4001
Berthaud P, LeChevalier T, Beridde J, Herait P, Baldeyrou P, Tursz T, Arriagada R, Spielmann M, Hayat M (1989) Phase II study of pirarubicin in advanced non-small cell lung cancer. Eur J Cancer Clin Oncol 25: 1337
Blum RH (1975) An overview of studies with Adriamycin in the United States. Cancer Chemother Rep 6: 247
Chabner BA, Myers CE (1985) Clinical pharmacology of cancer therapy. In: DeVito T, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology. J. B. Lippincott, Philadelphia, p 311
Conley BA, Hornedo J, Abrams J, Eisenberger M, Hiponia D, Aisner J, Van Echo DA (1987) Phase II trial of 4′-deoxydoxorubicin in advanced non-small cell lung cancer. Cancer Treat Rep 71: 861
Drings P, Günther IU, Gatzemeier U, Berdel W, Stahl M, Salewski E, Edler L (1990) Pirarubicin in advanced non-small cell lung cancer. A trial of the phase I/II study group of the Association for Medical Oncology of the German Cancer Society. Onkologie 13: 183
Gianni L, Vigano L, Surbone A, Ballinari D, Casali P, Tarella C, Collins J, Bonadonna G (1990) Pharmacology and clinical toxicity of 4′-iodo-4′-deoxydoxorubicin: an example of successfull application of pharmacokinetics to dose escalation in phase I trials. J Natl Cancer Inst 82: 469
Gianni L, Capri G, Greeo M, Villani F, Brambilla C, Luini A, Crippa F, Bonadonna G (1991) Activity and toxicity of 4′-iodo-4′-deoxydoxorubicin in patients with advanced breast cancer. Ann Oncol 2: 719
Mountain CF (1986) A new international staging system for lung cancer. Chest 89 [Suppl 4]: 225
Mouridsen HT, Alfthan C, Bastholt L, Bergh J, Dalmark M, Eksberg S, Hellsten S, Kjaer M, Peterson C, Skovsgård T, Sørensen JB, Tropé C, Aabo K (1990) Current status of epirubicin (Farmorubic in the treatment of solid tumors. Acta Oncol 29: 257
Ringenberg QS, Perry MC, Propert KJ, Modeas C, Hirsch V, We RB, Richards F, Graziano S, Green M (1988) Phase II trial of deoxydoxorubicin (DXDX) in non-small cell lung cancer: a Can and Leukemia Group B trial. Med Pediatr Oncol 16: 27
Rose C, Lad TE, Kilton LJ, Schir J, Rosen ST, Rossof AH, Blot RR, Johnson CM (1990) Phase II trial of 4′-deoxydoxorubi (DXDX) for unresectable non-small cell bronchogenic carcinor Invest New Drugs 8: 97
Rozencweig M, Kenis Y (1975) European studies with Adriamy in lung cancer. Cancer Chemother Rep 6: 343
Sessa C, Calabresi F, Cavalli F, Cerny T, Liati P, Skovsgaard Sorio R, Kaye SB (1991) Phase II studies of 4′-iodo-4′-deoxydi orubicin in advanced non-small cell lung, colon and breast cance Ann Oncol 2: 727
Simon R (1986) Confidence intervals for reporting results of clini trials. Ann Intern Med 105: 429
Sørensen JB (1993) Treatment in non small cell lung cancer: n cytostatic agents. Lung Cancer (in press)
Splinter TAW (1990) Chemotherapy in advanded non-small cell lung cancer. Eur J Cancer 26: 1093
World Health Organization (1979) Handbook for reporting results cancer treatment. Offset publication 42. WHO, Geneva
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sørensen, J.B., Stenbygaard, L., Drivsholm, L. et al. Phase II study of 4′-iodo-4′-deoxydoxorubicin in non-resectable non-small-cell lung cancer. Cancer Chemother. Pharmacol. 32, 399–402 (1993). https://doi.org/10.1007/BF00735927
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00735927